Premium
Vitamin K1 and Vitamin K2 immunopharmacological effects on the peripheral lymphocytes of healthy subjects and dialysis patients, as estimated by the lymphocyte immunosuppressant sensitivity test
Author(s) -
Kusano Junichi,
Tanaka Sachiko,
Matsuda Hiroto,
Hara Yoshikazu,
Fujii Yoshiaki,
Suzuki Shinya,
Sekiyama Masao,
Ando Eiki,
Sugiyama Kentaro,
Hirano Toshihiko
Publication year - 2018
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12747
Subject(s) - peripheral blood mononuclear cell , medicine , foxp3 , immunology , dialysis , lymphocyte , il 2 receptor , immune system , t cell , pharmacology , biology , in vitro , biochemistry
Summary What is known and objective Renal transplant recipients receive immunosuppressive therapy to prevent acute rejection. We evaluated the immunopharmacological efficacy of vitamin K1 ( VK 1) and vitamin K2 ( VK 2) on T‐cell mitogen‐activated‐peripheral lymphocytes of dialysis patients and healthy subjects. Methods The effects of VK 1 and VK 2 on the T‐cell mitogen‐stimulated proliferation of peripheral blood mononuclear cells ( PBMC s) obtained from 12 healthy subjects and 12 dialysis patients were estimated. Seven cytokines produced from the activated PBMC s were measured by a BD Cytometric Beads Array kit. Regulatory T cells (Tregs) in PBMC s were analysed as CD 4 + CD 25 + FoxP3 + lymphocytes by flow cytometry. Results VK 2 dose‐dependently suppressed the concanavalin A‐stimulated proliferation of PBMC s from healthy subjects and dialysis patients, whereas VK 1 had no significant effect on the PBMC proliferation. VK 1 and VK 2 did not influence the production of most of the Th1/Th2/Th17 cytokines from the activated PBMC s of these subjects, although VK 2 increased the IL ‐4 production from PBMC s of healthy subjects. The Treg percentages in the PBMC s of dialysis patients were markedly decreased compared to healthy PBMC s after the treatment with relatively low concentrations of VK 2. What is new and conclusion The present data suggest that VK 2 has immunosuppressive efficacy. VK 2 may enhance the immunosuppressive efficacies of glucocorticoids while preventing osteoporosis caused by glucocorticoids.